COPENHAGEN, Denmark, Sept. 19, 2018 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (`We`, `Forward` or the `Company` and together with its subsidiaries, the `Group`), today reported consolidated financial results for the six-month period ended June 30, 2018. Net loss for the six-month period ended June 30, 2018 was $(5.3) million, or $(0.06) per diluted share, versus net income of $941.2 million, or $1.67 per diluted share for the six-month period ended June 30, 2017. `We are pleased to announce our results for the first half year of 2018. The results reflect the effect of our strategic and organisational transformation initiated upon signing the Settlement and License Agreement with...
|
